Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives $53.40 Average Price Target from Brokerages

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have been assigned a consensus rating of “Moderate Buy” from the seven brokerages that are presently covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $53.40.

Several brokerages recently weighed in on COLL. Truist Financial set a $58.00 price target on Collegium Pharmaceutical in a research report on Tuesday, February 10th. HC Wainwright restated a “buy” rating and issued a $60.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, March 20th. Wall Street Zen cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Zacks Research lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $56.00 target price (up from $54.00) on shares of Collegium Pharmaceutical in a research note on Thursday, March 19th.

Insiders Place Their Bets

In other news, EVP David Dieter sold 13,976 shares of the stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $34.92, for a total transaction of $488,041.92. Following the sale, the executive vice president directly owned 77,071 shares of the company’s stock, valued at $2,691,319.32. This represents a 15.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Scott Dreyer sold 49,976 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $40.41, for a total value of $2,019,530.16. Following the sale, the executive vice president owned 71,770 shares in the company, valued at $2,900,225.70. This trade represents a 41.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 2.51% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Collegium Pharmaceutical

A number of large investors have recently bought and sold shares of COLL. Group One Trading LLC acquired a new stake in Collegium Pharmaceutical in the fourth quarter valued at approximately $28,000. Caitong International Asset Management Co. Ltd increased its position in shares of Collegium Pharmaceutical by 205.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock valued at $29,000 after buying an additional 427 shares in the last quarter. Federated Hermes Inc. raised its stake in shares of Collegium Pharmaceutical by 67.0% during the 3rd quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock worth $31,000 after buying an additional 350 shares during the period. Hantz Financial Services Inc. lifted its position in shares of Collegium Pharmaceutical by 137.7% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,714 shares of the specialty pharmaceutical company’s stock valued at $60,000 after buying an additional 993 shares in the last quarter. Finally, Kemnay Advisory Services Inc. purchased a new position in shares of Collegium Pharmaceutical during the 4th quarter valued at approximately $61,000.

Collegium Pharmaceutical Price Performance

Shares of COLL opened at $32.44 on Friday. The business’s 50-day moving average is $41.91 and its two-hundred day moving average is $41.74. The company has a market capitalization of $1.03 billion, a P/E ratio of 18.97 and a beta of 0.67. The company has a debt-to-equity ratio of 2.59, a quick ratio of 1.48 and a current ratio of 1.57. Collegium Pharmaceutical has a fifty-two week low of $23.23 and a fifty-two week high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.20 by ($0.16). Collegium Pharmaceutical had a net margin of 8.05% and a return on equity of 98.65%. The company had revenue of $205.45 million during the quarter, compared to analyst estimates of $206.36 million. During the same period last year, the firm earned $1.77 EPS. The business’s quarterly revenue was up 12.9% compared to the same quarter last year. Research analysts predict that Collegium Pharmaceutical will post 5.62 earnings per share for the current year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.